INTRODUCTION
In his seminal article, Bitter Pill: Why Medical Bills Are Killing Us, 1 Steven Brill recounts stories of Americans of modest to comfortable means, whose lives were turned upside-down, not just by tragic illness; but, by the cost of the cure. Sean and Stephanie Recchi, owners of a small start-up technology firm, discovered that his policy's $2,000/day cap did not come close to defraying six days in the hospital to develop a treatment plan ($48,900) and the initial doses of chemotherapy ($35,000) for his nonHodgkin's lymphoma treatment.
2 Feeling chest pains, Janice, a sixty-four (64)-year-old unemployed and uninsured woman, endured a four-mile ambulance trip, three hours of tests, and "some brief encounters with a Focusing on this relatively large group of patients will underline both the larger market failures in healthcare and their potential solution. Because this population is uniquely and disastrously affected by those market failures, addressing their concerns first serves both the demands of education and the demands of justice. We conclude that multiple failures in the healthcare market make it irresponsible to rely on market mechanisms to allocate healthcare resources. Reliance on price to clear the market fails miserably because only this vulnerable population is even remotely price-sensitive. Instead, we propose to limit that population's healthcare costs to the price allowed by Medicare. In doing so, the grossest excesses found in the system are curbed, without reducing the incentives for that population to seek the healthcare insurance that is more broadly available under the Patient 11 In its most recent report, the U.S. Census Bureau states that approximately 48 million individuals reported being without healthcare coverage for all or part of 2012. The number is statistically unchanged from 2011. CARMEN DENAVAS-WALT ET AL., INCOME, POVERTY, AND 
I. PATIENTS CAUGHT IN THE COST TRAP
Blessed with an embarrassment of riches, Brill unpacks the charges found in bill after patient bill. Just one example will highlight the looking glass quality of the "market." Returning to Steve Recchi's eight (8)-page invoice, Brill details how each product and service enjoyed a 400 to 1500% markup from their retail prices. Paradigmatically, a generic acetaminophen tablet (325 mg), currently priced on Amazon at 2.59 cents, 15 cost Recchi, $1.50. 16 In truth, you can't buy a single tablet on line. You must have the buying power sufficient to purchase in bulk; namely, a bottle of 1,000 tablets, which costs $19.12, or less than 2 cents per tablet. 17 Apparently, the hospital could not avail itself of the volume discounts that Recchi enjoys at Amazon. Recchi's experience is hardly unique. 14 Brill, supra note 1, at 43, 46-47. 15 A 100-pill bottle costs $2.59. Brill reports that he could purchase a 100-pill bottle for $1.49 on Amazon.com. Brill, supra note 1, at 18. 16 Id. 17 Id.
18 A billing advocate for another patient, Scott S., determined that Texas Southwestern Medical had triple-billed him for portions of his ICU treatment:
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The hospital's chargemaster, its ultimate billing source, appears to bear little, if any, relation, to the hospital's actual cost structure; rather, it appears to be simply an assessment of what the market will bear, like a "hypersteroidal rack rate." 19 Brill describes the document as an embarrassment to hospital officials, who "treat it as if it were an eccentric uncle living in the attic." 20 Nevertheless, with one important exception, it drives price for most healthcare consumers. That one exception is the government healthcare programs. Because of their market power and extensive cost databases, Medicare 21 and Medicaid, 22 pay only a tiny fraction of the chargemaster rate. In fact, the government does not even use the chargemaster as a guide, relying instead on its own assessment of the provider's cost structure. Large insurers, having less leverage than the government, pay a significantly higher price, usually discounted from the chargemaster rates. Smaller insurers, with still less leverage, enjoy smaller discounts off the chargemaster list. Individual patients, not covered by insurance, Medicare, or Medicaid receive the "special" chargemaster price. Incredibly, only those least able to pay, those without insurance or a First they charge more than $2,000 a day for the ICU, because it's an ICU and has all this special equipment and personnel. . . . Then they charge $1,000 for some kit used in the ICU to give someone a transfusion or oxygen. . . . And then they charge $50 or $100 for each tool or bandage or whatever that there is in the kit. That's triple billing.
Brill, supra note 1, at 17.
19 Tina Rosenberg, The Cure for the $1000 Toothbrush, N.Y. TIMES, Aug. 13, 2013, at 4, available at http://opinionator.blogs.nytimes.com/2013/ 08/13/the-cure-for-the-1000-toothbrush/. 20 Brill, supra note 1, at 22. 21 Rosenberg, supra note 19, at 4; Brill, supra note 1, at 43, 46-49. 22 Brill, supra note 1, at 46-49.
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ISSN If cost structure does not explain the hospital's price list, what does? One might expect healthcare competitors to be the key driver. Again, however, analysis leads only to mystification. Recently, the federal government has released the amounts hospitals charge for various procedures. 24 A joint replacement in Ada, Oklahoma, will cost $5300; in Monterey Park, California, $223,000. However lovely it is in Monterey Park, it is unlikely that the hospital's cost structure would be 42 times greater than it would be in Ada, Oklahoma. One might, nevertheless, be seduced by the notion that the two hospitals are simply in different markets. Being in the same geographic market does not, however, rationalize price. The same study reports that, in New York City, the charge for treating a blood clot on a lung can range from $29,869 to $51,580.
25 Admittedly, the range is dramatically less than the national range for joint replacement. However, it is still much greater than one expects in a truly competitive market. The seeming irrationality is not even readily explained by hospital's willingness to charge what the "market" will bear. "At Suburban Hospital in Bethesda, Maryland-serving an affluent community at the gates of the National Institutes of Health-the average charge for simple pneumonia was $5,284. Compare that to $79,365 at Hahnemann University Hospital in Philadelphia." A quick look at some of the comparable data 26 suggests that the much more affluent zip code of the Bethesda, Maryland, hospital is getting an incomprehensible deal: 23 Id. at 22. 24 Connie Cass & Lauran Neergaard, High hospital bills go public, but will it help, SEATTLE TIMES, May 8, 2013, available at http://seattletimes .com/html/health/2020944456_apushospitalcostsdisparity.html. 25 Id.
26 CITY-DATA.COM, http://www.city-data.com/zips (last visited May 3, 2014) (for the zip codes of both hospitals).
J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 7 Most of our 2010 healthcare debate revolved around who would pay for what kinds of care. Only at the margins did we begin to address the problem of how much we should pay for the care we receive. 27 Studies show that our national healthcare costs are dramatically higher than all other countries and our results are just as dramatically uneven.
28 For significant populations within the country, access to healthcare is more limited than it is for populations in some developing countries. 29 Evening out access to healthcare is directly related to the extraordinary costs of that care. If nothing is done about cost, the 48 million individuals who have become eligible for healthcare under the ACA promise to severely strain national resources.
30
However salutary it may be to assure (almost) universal access to healthcare, containing costs remains an unaddressed and potentially crippling reality. Remarkably, it has yet to be addressed.
Analytically, controlling costs is pretty straightforward. "Cost" has only two components: price and quantity (Cost = price x quantity). In our current system, most of our feeble cost containment efforts have focused on 27 See Brill, supra note 1, at 20. J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 8
ISSN controlling the quantity of medical resources consumed. Typically, insured patients are limited to acquiring prescriptions or healthcare services for only limited periods of time: an annual check-up, enough prescription medicine to last 30 days. Routine exams and tests similarly must meet some periodic limitation. Indeed, one can even view the "copay" as a quantity constraint, a disincentive to use medical services. Obviously, for the uninsured, both price and quantity do matter. For reasons discussed below, and alluded to above, they cannot do much about price. Many try to self-limit quantity, with potentially devastating consequences when the malady, easily addressed in its early stages, becomes expensive (and possibly untreatable) in its late stages.
Controlling quantity, however, has clearly not worked. While Brill reports of some incidents where patients appeared to "over-consume" medical resources, 31 that particular problem appears marginal. Most people do not find their lives so empty and lonely that they look forward to having it filled up with medical attention. Just living precludes that "luxury." Similarly, few of us are tempted by an inordinate desire to over-consume ordinary prescription drugs for diabetes, high blood pressure, cholesterol and other common maladies. They just don't taste that good; nor, do they promise much recreational value, prescription narcotics excepted. Greenspan to mutter anew about "irrational exuberance." The singularly high cost of healthcare in this country is not attributable to the quantity of healthcare products and services consumed. All evidence supports the proposition that the high cost of healthcare is driven by the price of healthcare. High prices and wild price variance 33 reflect some profound failures in the healthcare market. That prices vary so much within the same market testifies to the absence of expected market restraints, as will be discussed below. 34 The existence of (comparatively) low-price options only underscores the seeming irrationality. Yet, there remains a fundamental rationality to the exuberance. Providers charge those prices because they can. Some may just be more giddy (greedy?) than others. Moreover, providers can charge whatever they want, because every other player in the system (except one, the federal government) does not have to care about the price. While most patient-buyers cannot shop around, the uninsured patient is even more restricted to simply taking the random price demanded by the provider. As will also be discussed more directly below, 35 the inability to control price is rooted in major (and irremediable) market failures.
II. PRICE IS THE PROBLEM AND
In an article written over fifty years ago, Kenneth Arrow 36 pointed out how ill-suited are patient/consumers to be the leading spear for price control. They are (by definition) sick, unschooled in the subject matter (which is why they have turned to a professional), unschooled in the risks they confront (just by being human), uncertain whether any particular protocol will be successful, scared, and wholly ignorant of price. Rare is the patient who receives an array of possible remedies, each with an identified probability of success and an actual price. Indeed, it would be almost boorish to discuss cost J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 10 in such a vitally personal matter. 37 As discussed below, 38 even the loutish patient who might ask will find little reliable (and useful) data applicable to his situation.
Patients have generally ceded price control responsibility to their insurance companies, who have only a limited concern to control price. Typically, patients worry (some) about their deductible, and (less) about their co-pay. They expect that their insurance company will pick up the rest of the tab. Ultimately, however, insurance companies have no dog (or only a very tiny dog) in the price fight. If, in any current year, insurance payouts compromise profit expectations, the resulting difference becomes the basis for raising premiums the following year. Any one year's loss can be made up the following year. 39 With the implementation of the ACA, the incentive structure doesn't really change. If anything, it removes any remaining incentive for insurance companies to care. So long as their allowed 20% margin (for administrative costs and profit) is protected, any further savings, via negotiated price reductions, will be returned to the rate payer. If claims eat into the 20%, they simply provide the basis for a higher premium the following year. Underscoring how perverse the incentive structure remains, 20% of a larger number (i.e., increased costs) will only generate a larger revenue stream and, presumably, even greater profit in the following year.
One might look to the individual physician, who generally orders the care via prescription or referral, to serve as the bulwark against excessive prices. For a variety of reasons, some benign, some malignant, that hope is similarly misplaced. Even though physicians bill patients for services, the social norms preclude their acting simply as self-interested business owners. The norms themselves are unsurprising, given the fiduciary character of the relationship. The patient goes to a physician to get both a diagnosis and a treatment. Virtually ignorant of the elements of either prong of the consultation, the patient must rely on the physician's expertise and integrity. 37 Id. at 964-66. 38 Infra notes 40-45 and accompanying text. 39 Rosenberg, supra note 19, at 2.
J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 11 For that reason, physicians are typically forbidden (or discouraged) from advertising or engaging in overt price competition. 40 Their medical advice must be devoid of self-interest. 41 Treatment prescriptions are presumed driven by case requirements and ought not to be limited by financial considerations. These long-standing norms reinforce a level of physicianpatient trust that makes discussions of price almost unseemly and, not surprisingly, give birth to acts of individual medical charity for the indigent and the related price-discrimination among affluent patients. 42 Other factors also limit the physician's role in cutting costs. Not surprisingly, physicians want to have available as broad an array of remedies for their patients' ailments as is possible. 43 Considering cost limits that array. Consistent with a disdain for and/or discomfort with money being interjected into considerations of care, physicians, not unlike their patients, are often wholly ignorant of the price of their various healthcare remedies. 44 Indeed, they may be as ignorant of costs as are their patients. One physician, David Belk, MD, chronicling his own epiphany, captures the problem of physician ignorance in his opening statement on why medical costs are so high.
Why didn't we know [why medical costs were so high]? To start with, unlike any other business in America, almost all of the financial transactions in healthcare are hidden from the providers as well as the patients. We order test, procedures and medications to manage our patients, but very few doctors, or other healthcare providers, have any idea how much any of those things cost. Patients only rarely pay directly for these services and payment for any service varies substantially from different payers. Hospitals have separate billing 40 Arrow, supra note 36, at 949. 41 Id. 42 Id. at 953. 43 Belk, supra note 32, at 4. 44 
Id.
J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 12 In summary, none of the principal sources of consumption-neither the patients, their families, nor their immediate healthcare providers (their own physicians)-are in a position even to know what the costs are of a procedure, let alone control those costs. The insurance company is in a slightly more advantaged position, having likely negotiated prices for specific procedures, as well as prescriptions and equipment. That, however, is not the same as knowing the cost of the procedure. Indeed, for most insurance companies, the price is simply a "discounted" chargemaster price. 46 However, if, as is usually the case, the chargemaster is a multiple of 10-15 times the provider's actual cost, 47 a "whopping" 50% discount is something less than a negotiating coup. The healthcare system is like a rigged game of poker, 48 where the patient, especially if not insured through either his employer or the government, is the ultimate patsy.
Notwithstanding these obvious flaws in the system, there are still many who advocate that the real cure for healthcare is to allow the free competitive marketplace to work its magic. 49 This would assure resolution of both our 45 Id. 46 Brill, supra note 1, at 23
47 See Rosenberg, supra note 19, at 4. 48 Brill, supra note 1, at 54 (calling it "a crapshoot"). cost and access issues. 50 Prices would drop and quantity is unlikely to rise, given the low marginal utility of overconsumption. 51 If prices drop and quantity remains stable, costs must also drop. However, as opponents of the ACA pointed out, the second element of the healthcare issue, access, dramatically affects the first element, costs. Quantity cannot remain stable if somewhere between 35 and 45 million citizens 52 are to be provided healthcare under the enactment. Even after accounting for the efficiencies resulting from early diagnoses and treatment of potentially serious and expensive illnesses, filling the system with that many "new" consumers has to increase quantity and, ultimately, cost.
One suggested answer is simply to bar the door. It was captured succinctly in the 2012 Republican primary debates, when Rep. Ron Paul was asked whether society should pay for the emergency care of a young man in a coma who had chosen not to purchase insurance. To make the hypothetical work, one has to assume that the man now had no assets (money or insurance) to enable him to purchase the needed treatment. Paul was asked how he would address the dilemma of the uninsured comatose patient. The candidate stumbled 53 a bit, as he said that people make decisions and need to expect to live (presumably, no pun intended) with the consequences of those decisions. Obviously, in the non-hypothetical world, few adults "choose" to go without healthcare coverage, except when they cannot afford it. To extend Paul's comments to the broader societal question of indigent healthcare, Paul would be referring to the Everyman's "decisions" that had left him without RONPAUL.COM (Nov. 6, 2009), http://www.ronpaul.com/2009-11-06/ronpaul-on-free-markets-regulation-auditing-the-fed-and-healthcare/. 50 J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 14 assets and not his "decision" to have a heart attack. When Wolf Blitzer pressed him, would Paul "let him die?" a number of his (presumably) supporters shouted "Yes," to general applause from the audience.
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However problematic are the ethics underlying such an ethos, the law has already addressed the policy issue. If the man did not have the resources, he would, depending on his age, be covered under either Medicare or Medicaid. Moreover, as a matter of federal law, no one may be turned away from a hospital simply for lack of funds.
55 Such a longstanding statutory expression of public policy, makes it unlikely that the Paul supporters could rally public support for their chilling view of public policy. As it stands now, the indigent and the elderly have affordable healthcare through the government, who successfully sets prices for healthcare services. The next large group of healthcare consumers is "protected," at least to some extent, by employer provided health insurance companies. A much smaller segment purchases its own insurance. Unlike the government "carriers," insurance companies are not as successful at controlling prices. While Medicare and Medicaid, armed with an incomparable database and genuine market power, can simply ignore the chargemaster, insurance companies exploit their more limited leverage to reduce the amount of chargemaster-based prices. 56 The most vulnerable population is the one group that is neither protected by the government nor by an insurance company. Only that group's members are caught up in a completely rigged "free" market.
III. THE MARKET IS THE PROBLEM; NOT THE SOLUTION
Given the political attractiveness for those who would "set the market free," it serves to recall some basic conditions for the existence of a competitive free market. The list is short: 54 
Id.
55 Emergency Medical Treatment and Active Labor Act § 9121, 42 U.S.C. § 1395dd (1986). 56 Brill, supra note 1, at 43-44, 46-49.
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A. NUMEROUS BUYERS AND SELLERS AS PRICE-TAKERS
Clearly, the healthcare market fails on most or all of these component parts. Depending on how one looks at the "market," one can argue that there are numerous buyers and sellers; but, it cannot be said that all of the players are price-takers. Certainly, Medicare and Medicaid patients are protected by a price-maker. Depending on the financial strength of their respective carriers in the relevant local and national markets, privately insured patients enjoy a modest protection from healthcare providers by dint of their carriers' ability to negotiate some price concessions. While the uninsured, non-government protected patient-buyer is a price-taker, the same cannot be said of the correlative provider-seller. Whether it is a pharmacy, a private physician, or a hospital/medical institution, the provider alone (if then) sets the price. Moreover, as medical care providers, especially hospitals merge and J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 16 incorporate more private physicians into their networks, their market power increases. As that process accelerates, the market power of their primary foil, insurance companies, diminishes. 58 The effect of this consolidation is to reduce the number of providers, affording the remaining ones the leverage to more closely approximate their chargemaster wish list.
B. BARRIERS TO ENTRY AND EXIT
Depending on one's place in the market, there are multiple barriers to entry and exit. For the patient, death is the only "viable" exit strategy. While some health problems may be ignored for a while, few of them ever age well. Only those who suffer a quick and untimely death can actually exit the market. That, however, is a one-time only option. Nevertheless, even most in that select population entered the market upon entering life. By any definition, patients form a captive market. For providers, also, there are certainly barriers to entry. One of the most profound barriers is represented by the strict rationing of places in medical school, which constricts the number of physicians in the marketplace, 59 leading to a consequent oligopoly. With increasing consolidation of healthcare facilities, via mergers and acquisitions, the healthcare industry (at the institutional level) further raises the barriers to competitive entry, while reinforcing its oligopolistic (and even monopolistic) systems.
60

C. PERFECT INFORMATION
As virtually every writer has observed, 61 buyers have almost no information about market conditions. For most patients, knowledge about 58 Rosenberg, supra note 19, at 2, 3; Brill, supra note 1, at 40, 55. 59 Arrow, supra note 36, at 952. 60 See Brill, supra note 1, at 40. 61 E.g., id. at 40, 54; Belk, supra note 32, at 4; Arrow, supra note 36, at 962 (noting that insurance removes even the incentive for the central players-physicians and patients-to price shop); Rosenthal, supra note 19, at 4. J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 17 price, quantity, and quality is virtually inaccessible. There is no price transparency whatsoever. Typically, patients are never advised of price until after the transaction has taken place. 62 However, even if the patient were to be told in advance of the price of a procedure, it would not help much. More likely than not, the patient would be given the chargemaster rate, unadjusted for discounts negotiated by the patient's public or private carrier. 63 Even if such price information were available, it is unlikely that similar information would be available from competing providers that would make the information relevant to a decision. Finally, even if such information were available from both the expected provider and competitors, the typical patient has no means to evaluate the information and is often too stressed to evaluate it. 64 Alternatively, the patient is too ill, even unconscious, to engage in comparison shopping, whether of the on-line or on-foot variety. Finally, it may well be that the patient's physician probably only has privileges at one, or maybe two, institutions available for the procedure. 65 The problem of knowledge in and of the marketplace actually is even more acute. In the case of services, the physician may not have much knowledge about the comparative merits of the available institutional choices. 66 Moreover, he/she may have familiarity with or be restricted to practicing in only one of the available choices, creating an implicit conflict of interest between physician and patient. Further, the physician may well be as clueless about the cost-benefit analysis as is his/her patient. 67 Finally, most 62 Brill, supra note 1, passim. J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 18 institutional providers, as well as individual providers, cannot say what a procedure/remedy will cost, without first knowing the patient's specific insurance plan. Obviously, if there is no patient insurance, that complication is removed; but, at an enormously greater cost; that is, by ready reference to the chargemaster. 68 In many cases, the attending physician may be just as unaware of price and quality when it comes to prescriptions or medical equipment. 69 Moreover, even if the physician knows what the list price is for the goods, he/she would almost certainly not know what the carrier's particular discount is, or even if the patient is covered by insurance at all. Below, we discuss specifically how physicians compromise their judgment by holding a financial interest in the remedy prescribed-whether pharmaceuticals, devices, or equipment.
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D. FUNGIBLE GOODS AND SERVICES
With regard to the fungible quality of healthcare goods and services, the results are mixed. With regards to services, it would appear that the softer qualities of the physician-patient relationship argue for lack of fungibility. Nevertheless, the entire medical industry has relied for decades on an elaborate encoding system for payments related to each medical procedure, a system which argues for greater fungibility. 71 Both government and private carriers have embraced the coding system. 72 One would expect that there be greater fungibility among healthcare goods such as prescriptions and medical equipment. On the surface, that is actually true. In practice, the situation is more complicated. For a variety of reasons, doctors prescribe different medications, medical equipment, and therapies. The variance can be attributed in part to physician awareness of a patient's unique health 68 Brill, supra note 1, at 54 69 Belk, supra note 32, at 4. 70 Infra notes 73-76 and accompanying text. 71 Brill, supra note 1, at 48. 72 
Id.
J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 19 requirements, to physician familiarity and comfort with certain protocols (with attendant efficiencies), or just availability in a particular region.
More troubling, however, is the growing practice of physicians' receiving significant compensation from companies whose medical devices (e.g., joint replacements, heart "parts," such as defibrillators, valves, etc.) they adopt. 73 The compensation can take the form of "stock options, royalty agreements, consulting agreements, research grants, and fellowships." 74 Whatever the form, it raises serious conflict-of-interest issues that certainly could direct patient "choices" and even lead to over-prescription. 75 Rarely, however, would the patient even know the price of the prescribed equipment, how it compares to similar types of equipment, or the nature of his physician's financial interest in the "choice." 76 In any event, the argument for fungibility is seriously compromised.
E. NO EXTERNALITIES
The requirement that there be no externalities in a perfectly competitive market (or even a "tolerably" competitive market) may be the element least often found in healthcare. An externality is any cost or benefit from a transaction that is borne or enjoyed by a party who is not a participant in the transaction. 77 With the one possible exception that is the ultimate focus of this examination, virtually every provider-patient transaction involves thirdparties, and consequent externalities. Patients receive treatment and, only rarely, pay for it (or for most of it). The federal government, with state support, pays for the treatment of the elderly and indigent patient. Similarly, 73 Id. at 34. 74 Brill, supra note 1, at 34. insurers guarantee (some) payment; but, do not receive treatment. Both the government and the private insurer are affected by cost. The government is accountable ultimately to tax payers. The insurance company is accountable to shareholders. Because of data and leverage, the government can positively (from its perspective) affect the cost of the transactions. 78 Insurance companies have less leverage; but, an obvious escape hatch. If they cannot match their costs stream with their premium stream, they can always raise premiums in the next year. 79 Unlike the government, which is loath to raise taxes, insurance companies can always raise their rates, forcing employers and the insured to absorb the price increases. Employers continue to pay for insurance; but, do not receive the treatment. For them, healthcare expenses are a source of worry and concern, without much of a lever to control either element of cost price or quantity.
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That leaves only the providers and the patient. While some providers are as uninformed as are their patients, 81 others are just happy to provide as much care at as high a cost as possible. Their motivation is uncomplicated in the extreme. Patients also fall into two, albeit different groups. Virtually all patients are ignorant of pending costs. Most insured patients, however, simply do not care what the cost is. After paying their deductible (and, usually, small co-pays), they know only that someone else will pick up their remaining tab.
What remains are those patients without either public or private insurance, or are insufficiently insured. Their experience of externalities is primarily negative. Unlike their insured counterparts, they care intensely about cost. Like their insured counterparts, however, they neither know the price of what they are buying nor have the emotional temperament to rationally weigh obscurely defined options in major life or death decisions or, 78 See Rosenberg, supra note 29, at 4. 79 Rosenberg, supra note 19, at 2 and 4; e.g., Brill, supra note 1, at 4, 37-38. 80 Rosenberg, supra note 19, at 4.
81 See Belk, supra note 32, at 4 and accompanying text.
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ISSN 2164-7976 (online) DOI 10.5195/pjephl.2014.76 http://pjephl.law.pitt.edu Winter 2014 less dramatically, major health decisions. 82 Moreover, as pointed out above, even if they could know their costs for each option in advance of purchase, and even if they could rationally assess those options, they lack the bargaining power of either the insurance companies or the federal government. 83 The ultimate perversity in the system is that providers look to this last pool of consumers to subsidize the profits they have relinquished to those with significantly more market power; namely, the government and insurance companies. In effect, this population subsidizes the rates of the variously insured populations. As a result of their lack of market power, they forgo much preventive care, and with it, early diagnosis. As observed above, 84 undiagnosed health problems seldom improve with age. When those problems can no longer be ignored, they require very expensive attention and frequently a consequent bankruptcy. 85 Unplanned and expensive healthcare issues represent the largest single cause of Chapter 7 filings. 86 Bankruptcy is the final externality. For the patient it offers of the hope of a "fresh start:" albeit one, without their former assets, often accumulated over a lifetime. For the hospital, it represents a loss of a peculiar nature. It is a loss calculated at the bloated chargemaster rate and then written-down as bad debt for taxpurposes. Given the nature of the chargemaster, the tax recovery is typically greater than the original cost (or even "retail" value) of the medical services provided.
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F. BUYERS ARE UTILITY MAXIMIZERS
Economists assume that consumers, including healthcare consumers, make their market choices by opting for the most preferable bundle of goods, 82 Brill, supra note 1, at 23; Arrow, supra note 36, at 949, 964-65. 83 Brill, supra note 1, at 22. 84 Supra at text between notes 30 and 31. given their resource constraints. 87 Perhaps the shakiest part of the assumption is that healthcare consumers are capable of rationally maximizing their utility. Given the opaqueness of the market, 88 healthcare consumers have ceded considerable control to their physicians and, for the more fortunate with insurance, to their insurance providers. Nevertheless, one can consider the unavoidably ignorant, and frequently anxious, patient as maximizing his utility by simply relying on the counsel of his physician, who may well share the patient's ignorance of the cost of medical goods going into the market basket. 89 In the case of the uninsured, it is simply a matter of foregoing the "luxury" of a diagnosis, or the resulting prescriptions for, say, high blood pressure or incipient diabetes, to assure that the patient and her family remained fed, clothed and housed, To the onlooker, it appears a Hobson's choice; to the patient, it is utility maximization. For purposes of this analysis, however, the writers assume that the healthcare market meets the condition of utility maximization.
G. NO EXTERNAL PARTIES REGULATE PRICE, QUANTITY OR QUALITY OF THE GOODS AND SERVICES EXCHANGED IN THE "MARKET"
It would seem to go without saying that there exist a number of sources of external regulation in the healthcare markets. While free market advocates might want to look first at fixing this market "deficiency," the problem is neither simple nor easily resoluble. No one seriously disputes that the development of drugs (prescription and non-prescription) and medical devices is highly regulated. Reducing that regulation might produce greater efficiencies in getting drugs and devices to market. However, the benefits of such a policy would need to be weighed against the prospect of more tainted 87 SAMUELSON & NORDHAUS, supra note 57, at 87. 88 See supra notes 61-70 and accompanying text. 89 Belk, supra note 32, at 4. J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 23 drugs, drug frauds, and quack remedies. 90 Given the complexity of the products available, it is hard to fathom how the market (made up either of attending physicians or their patients) could begin to evaluate the claims of competing manufacturers. Dissecting that problem (or promise?) goes beyond the scope of this paper. However, regulation, actual and potential, does not end there.
Currently, the market "regulates" physician malpractice with individual and class actions. A patient's claim is tested in a court of law, usually by a jury. Plaintiffs' personal injury attorneys, compensated by contingent fees, represent the most market-driven portion of the bar. Because every case represents a major investment of time and money, attorneys have to prudently assess which cases have merit and which are black holes. Imprudent assessments make for hungry attorneys. Nevertheless, the process is cumbersome, idiosyncratic, costly, and time-consuming. For all these reasons, there is a growing movement for malpractice reform. One proposal is to provide a "safe-harbor" defense to physicians. Physicians and hospitals could invoke the defense by showing that the symptoms presented did not call for the unreasonable expense avoided. 91 The test for "reasonableness" would be established by peers within the medical community; not by experts in the courtroom. 92 The proposal could reduce incentives to overuse expensive testing and diagnostic procedures merely to avoid later claims that a case would not have had the unfortunate result that gave rise to the suit.
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Of course, the proposed reform does not address the other incentive to overuse diagnostic protocols; namely, that they are such an easy and lucrative way to increase revenues for hospitals and for private practices. 91 Id. 92 Id. 93 Brill, supra note 1, at 55. 94 Id.
J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 24 There is, however, another form of external regulation designed expressly to keep healthcare costs high. While Medicare and Medicaid have been enormously successful in keeping their per-patient payout to a (comparative) minimum, 95 with regard to healthcare services 96 the same cannot be said for the purchase of prescription drugs. The two government programs are prevented by law from restraining prices for drugs, as is commonly done in other countries. 97 Indeed, the two programs are even prohibited from using their considerable buying power (Medicare is the single largest buyer 98 ) to negotiate lower drug prices. Instead, Medicare is required to pay 106% of the average sales price for prescription drugs. 99 The catch is that the pharmaceutical companies set the price.
100 This is especially problematic when patents guarantee a monopoly-pricing opportunity. If the patient only has a copay of five (5) to thirty (30) dollars, the patient will rarely complain. If the insurance company overpays on a new drug, it can recover with higher premiums the following year.
Quite possibly, the most expensive example of protective legislation comes from Congress' barring Medicare from getting into the comparative effectiveness debate. If exhaustive comparative studies show that one drug, which costs dramatically less than a second drug, actually has the same or better results, Medicare should be able to say it will only cover the less expensive drug, forcing an efficiency that does not compromise care.
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95 Estimates of cost structures suggest that even Medic are and Medicaid could tighten up their compensation for services, without throwing the medical profession to the wolves. Brill, supra note 1, at 55. 96 E.g., id. at 46-49. 97 Id. at 46. 98 
Id.
99 42 C.F.R. § 414.904 (the lesser of the actual charge or 106% of average sales price). 100 Brill, supra note 1, at 43. 101 Id. at 46.
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Multiple externalities make cost-control almost meaningless. 110 Insured patients (that is, "fully insured") can afford the luxury of not attending to cost. Insurance companies can recover in the following year and providers can ratchet up price on the uninsured to cover lost profits resulting from having to bargain with the "market's" stronger players. While one can attempt to argue that patients are utility-maximizers, they remain so stressed and unavoidably ignorant that the necessary qualifier "rational" is oxymoronic. Given enormous constraints of knowledge, access, and resources, patients make the best of what they can with their limited options. Acknowledging those constraints compromises any characterization of patients as utility maximizers.
Finally, this market has been and will remain heavily regulated.
111
Protecting the life and health of the public is both an individual and corporate concern.
112 Primarily, healthcare regulation has focused on quality assurance, expanding access, and cost control. 113 It is hard to imagine policy makers eschewing any one of those three goals. Obviously, the expected expansion of access to the healthcare system presents challenges to other two goals of quality assurance and cost control. Given that healthcare will continue to have an outsized presence 114 in the American economy, both economic and policy reasons make significant deregulation unlikely.
Because it involves the exchange of goods and services, the healthcare system can be called a "market." By almost every indicia (making some allowance for the fungibility and utility maximization conditions), however, it is not, and has not been for decades, a competitive market. It is much more J o u r n a l o f E n v i r o n m e n t a l a n d P u b l i c H e a l t h L a w P a g e | 27
ISSN 2164-7976 (online) DOI 10.5195/pjephl.2014.76 http://pjephl.law.pitt.edu Winter 2014 like a casino, in which only the patient does not get to see the cards being played. This is especially true when one considers the plight of the uninsured patient. As healthcare expenditures approach a quarter of our GDP, getting a handle on cost is critical for society at large. 115 For the uninsured, the situation is more dire. For many, it represents a choice between death and bankruptcy.
Mastering the Chargemaster
IV. RESPONDING TO THE PLIGHT OF THE UNINSURED PROVIDES A LABORATORY FOR TESTING THE BROADER CHALLENGES OF REGULATING THIS MARKET
The economic conditions surrounding healthcare call for some major intervention. As long as conditions remain as described herein, the United States will continue to see healthcare costs soar, without a parallel improvement in quality of the results. One remedy, to universalize Medicare coverage, was hinted at during the ACA debates. 116 At the time, it was politically untenable and probably remains so. 117 Given almost catastrophic market failure, the problem calls out for a legislative solution. While our current Congress may simply blink in the face of this public policy challenge, it could try a "small-bore" response to a much graver individual problem.
The one truly vulnerable "player" in the market is the uninsured patient. With virtually no institutional forces to provide cover, the patient is a ready mark for profit and "non-profit" 118 healthcare providers, especially if
